Oncology & Cancer

CAR T therapy shows long-lasting remissions in non-hodgkin lymphoma

A significant number of non-Hodgkin lymphoma (NHL) patients in a Penn Medicine-initiated clinical trial continue to be in remission five years after receiving the chimeric antigen receptor (CAR) T cell therapy Kymriah, researchers ...

Medical research

Breyanzi approved for certain types of large B-cell lymphoma

Cell-based gene therapy Breyanzi (lisocabtagene maraleucel) has been approved to treat adults with certain types of large B-cell lymphoma who have not responded to other systemic treatment, the U.S. Food and Drug Administration ...

page 9 from 40